BPC-157
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
BPC-157 and TB-500 Do Different Things on Paper. The Blend Ratio Is Still Somebody's Guess.
Two distinct proposed mechanisms, one shared evidence ceiling, and no published study that tested the pair against either compound alone.
BPC-157 Isn't "Only Rat Studies." It's Tier 2, and That's the Argument You Should Be Having.
The claim everyone repeats is factually wrong and directionally right, here's the evidence ladder that settles it in one question.
BPC-157 Wasn't Banned. It Was Left Off a List.
Four separate regulatory facts get crushed into the word 'legal,' and almost every confident answer online is answering a question you didn't ask.
How it is thought to work
Potential effects on angiogenesis, tissue signaling, and repair pathways.
BPC-157 is a small synthetic peptide originally found in stomach juice that researchers study for its effects on tissue repair, blood vessel growth, and gut healing in animal models, though human evidence is still very limited.
Reported side effects
In the very small amount of human pilot data available, BPC-157 was reported as well-tolerated with no detected organ toxicity, though mild injection-site redness is the most commonly noted short-term issue in community use.
Who should avoid it
People with active or prior cancer, those who are pregnant or breastfeeding, competitive athletes subject to drug testing, anyone on blood-pressure-affecting medications, and anyone seeking an approved medical treatment should avoid BPC-157.
What gets monitored
Blood pressure monitoring during the research cycle is suggested. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for BPC-157 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 250-500 mcg once or twice daily | once or twice daily4-8 weeks · 4-8 week cycles, may repeat after a break | subcutaneous | Commonly published practitioner dosing range - provider confirmation required. |
| Standard: 250 mcg twice daily · Low: 250 mcg once daily · High: 500 mcg twice daily | Twice daily4-6 weeks · Standard | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: under 30 minutes. The standard dosing for BPC-157 is 250 mcg twice daily. |
| 250-500 mcg | Twice daily (morning and evening)4-6 weeks | subcutaneous or oral or topical | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Referenced at 200-500 mcg (0.2-0.5 mg) daily overall; recovery contexts cite 200-400 mcg once or twice daily, commonly right after training. Oral form referenced as viable for gut-focused use. | 1-2x daily · Morning for systemic or gut focus; post-workout for tissue repair; before bed for overnight healingOn-cycle 4-6 weeks, off-cycle 1-2 months | subcutaneous, intramuscular near injury, or oral | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- once or twice daily4-8 weeks · 4-8 week cycles, may repeat after a break
- subcutaneous
- Commonly published practitioner dosing range - provider confirmation required.
- Twice daily4-6 weeks · Standard
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: under 30 minutes. The standard dosing for BPC-157 is 250 mcg twice daily.
- Twice daily (morning and evening)4-6 weeks
- subcutaneous or oral or topical
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- 1-2x daily · Morning for systemic or gut focus; post-workout for tissue repair; before bed for overnight healingOn-cycle 4-6 weeks, off-cycle 1-2 months
- subcutaneous, intramuscular near injury, or oral
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- Commonly supplied as 5 mg or 10 mg vials · Reconstitute lyophilized powder with bacteriostatic water; refrigerate after mixing
- 2 mL BAC water
- Bacteriostatic water
Common questions
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice.
What does BPC-157 do?
In animal studies, BPC-157 supports new blood vessel growth and helps cells migrate into injury sites.
Is BPC-157 FDA-approved?
No, BPC-157 is not an FDA-approved drug.
Why is BPC-157 banned by WADA?
WADA bans substances that lack regulatory approval for human use, including BPC-157.
How is BPC-157 commonly dosed in research planning?
Typical dosing is about 250 mcg once or twice daily by subcutaneous injection.
Can BPC-157 be taken orally?
Yes, BPC-157 is stable in human gastric juice, allowing for oral administration.
How is BPC-157 reconstituted?
A 10 mg vial reconstituted with 2 mL bacteriostatic water yields 5,000 mcg/mL.
Check 10 mg in 2 mL in the calculator →What are the main side effects of BPC-157?
Common side effects include injection-site redness or small bumps, with theoretical risks related to cancer.
Sources
- 01Lee et al., Alternative Therapies in Health and Medicine, 2025
- 02Sehgal et al., Pharmaceuticals, 2025
- 03He et al., Frontiers in Pharmacology, 2022
- 04Sikiric et al., Current Pharmaceutical Design, 2011
The reference sections above are imported from our compound knowledge base, which classes the evidence for BPC-157 as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Peptide blend of GHK-Cu, BPC-157, and TB-500, studied for skin quality, tissue repair, and recovery.
LL-37 is the only known human cathelicidin-derived peptide (37 amino acids), studied in antimicrobial and innate-immunity research models.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.